Another Award for the Sturdza Family Fund
Having reached its third anniversary in December 2021 the Sturdza Family Fund and the investment team became eligible for consideration by a number of the industry’s independent rating agencies.
To date, the Fund has received 4-star and 5-star Morningstar ratings (depending on the share class); a 5-Globe ‘High’ Morningstar Sustainability Rating (putting the Fund in the top 10% of all Funds within its peer group) and three of the investment team have been rated by Citywire. These all speak to the quality of the management of the Fund, particularly from a risk-adjusted perspective.
We are pleased to advise therefore the Fund has received further recognition, from FundsPeople. They have classified the Sturdza Family Fund as one of their "Distinguished Investment Products of the Year" within their 2022 Fund ratings in Italy and Spain.
The Sturdza Family Fund has been recognised for the consistency of the returns, with reference tovolatility versus its Morningstar-defined peer group. Additional information regarding FundsPeople’s assessment methodology is provided below.
About the Sturdza Family Fund
The Fund was launched to capitalise on Eric Sturdza’s long-term approach to investing, with a focus on high growth and stable companies, whilst seeking to reduce volatility through a diversified flexible allocation portfolio. The Fund is an important component in the Sturdza Family’s own wealth management strategy.
Accordingly, the team is composed of experienced and complementary managers and advisers, with diverse backgrounds and in-depth knowledge of their respective asset classes, to support the delivery of the investment objective over the long term.
Today the team consists of seven individuals, including Eric and Constantin Sturdza. Through this Fund, we seek to give long-term investors the opportunity to invest alongside the Sturdza family ensuring a true alignment of interests.
Commenting on the recognition from FundsPeople, Constantin Sturdza said: “We are delighted that the Sturdza Family Fund has been recognised by FundsPeople for the risk-adjusted returns that have been achieved since inception in 2018. The macro environment has been volatile and unpredictable at times; however, we as a team are proud that the strategy has achieved our objective, based on long-term principles, with a focus on value creation.
We are continuously looking at ways to enhance our approach and adapt to the investment environment we face, with the aim of ensuring we continue to serve our clients in a unique way and in doing so maintain a total and relatively unparalleled alignment of interest as cornerstone investors ourselves.”
The FundsPeople Rating Methodology
For seven years, FundsPeople has been evaluating funds based on three criteria to identify the products, in each market, that have demonstrated consistent results compared to their peer group and are considered to be among the best bets according to fund selectors or have a significant heritage in the specific market. FundsPeople believes that a fund that meets at least one of these criteria is worthy of recognition in the so-called FundsPeople Ratings.
As noted, the Sturdza Family Fund was selected based on the consistency of the risk-adjusted returns. These are analysed by the team at FundsPeople utilising their own quantitative model which identifies the most consistent funds within each category (Morningstar Category).
The initial stage of the process considers the entire universe of funds available for sale in the relevant market, with profitability data for more than three years at the end of the relevant calendar year (2021 in this instance). Only the oldest share class that is available for sale in the market under consideration is utilised in this regard.
The focus of the team at FundsPeople is to identify how each fund has behaved based on two variables: profitability and volatility, in base currency terms. They compare each fund within the peer group using two scorecards.
The first considers cumulative profitability and volatility data over three and five years; whilst the second considers these metrics over the last five calendar years (2017, 2018, 2019, 2020 and 2021). In both cases, profitability and volatility are weighted 65% / 35% respectively. Each scorecard ranks the funds within the peer group, with those within the first quintile receiving a rating.
Get in touch
For further information regarding the Sturdza Family Fund, the investment team or to receive additional materials please contact info@ericsturdza.com or visit the fund page on ericsturdza.com.
The views and statements contained herein are those of Banque Eric Sturdza SA in their capacity as Investment Advisers to the Fund as of 27/06/2022 and are based on internal research and modelling. Please refer to ericsturdza.com for full disclaimers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005073/en/
Contact information
Viali Munteanu
ericsturdzainvestments@cognitomedia.com
07547819438
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
